Immunotherapy News and Research

Latest Immunotherapy News and Research

Jennerex Phase 2 JX-594 clinical data for hepatocellular carcinoma presented at ILCA meeting

Jennerex, Inc., a private, clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic immunotherapies, presented Phase 2 clinical data of JX-594 delivered first intravenously and subsequently through intra-tumoral route demonstrating safety as well as disease control and tumor responses in patients with hepatocellular carcinoma (liver cancer, HCC).

17 Sep 2012

Janssen, ImmuNext partner to develop novel cancer therapeutics

ImmuNext, Inc., today announced that it has entered into an agreement with Janssen Biotech, Inc., focused on the development of novel therapeutics that modulate the immune system for the treatment of cancer.

6 Sep 2012

ImmunoCellular completes enrollment in ICT-107 Phase II trial for glioblastoma

ImmunoCellular Therapeutics, Ltd. announced today that the company has completed enrollment for its Phase II randomized, double-blinded, placebo-controlled, multi-center trial of its dendritic cell-based cancer vaccine ICT-107 for treatment of glioblastoma.

6 Sep 2012

ImmusanT commences Nexvax2 clinical trials for celiac disease in New Zealand, Australia and the U.S.

ImmusanT announced today that it has initiated clinical trials in New Zealand, Australia and the U.S. to evaluate Nexvax2, the first therapeutic vaccine for patients with celiac disease. Nexvax2 is designed to re-establish patients' tolerance to the toxic effects of gluten, a protein in wheat, barley and rye, and allow them to return to a normal diet.

5 Sep 2012

EC grants marketing authorization for Pfizer’s INLYTA to treat renal cell carcinoma

Pfizer Inc. announced today that the European Commission (EC) has granted marketing authorization for INLYTA (axitinib) for the treatment of adult patients with advanced renal cell carcinoma (RCC), a type of kidney cancer, after failure of prior treatment with sunitinib or a cytokine.

4 Sep 2012

Potassium-channel autoimmunity linked to chronic pain

A substantial proportion of patients with voltage-gated potassium channel-complex autoimmunity experience chronic idiopathic pain, although the specific antigenic complex associated with pain remains to be determined, conclude US scientists.

3 Sep 2012

VLST, Pfizer enter in-licensing agreement for anti-CD40 monoclonal antibody

VLST Corporation, a Seattle-based biotechnology company focused on the development of therapeutics for cancer and autoimmune and inflammatory disorders, today announced an in-licensing agreement with Pfizer Inc. for an anti-CD40 monoclonal antibody.

31 Aug 2012

Promising results with SLIT for childhood grass pollen allergy

High-dose sublingual immunotherapy effectively reduces allergic symptoms and medication use in children with grass pollen–allergic rhinoconjunctivitis, show study results.

31 Aug 2012

Study explains why some cancer vaccines are not as effective as hoped

A research report published in the September 2012 issue of the Journal of Leukocyte Biology offers a possible explanation of why some cancer vaccines are not as effective as hoped, while at the same time identifies a new therapeutic strategy for treating autoimmune problems. In the report, scientists suggest that cancer, even in the very early stages, produces a negative immune response from dendritic cells, which prevent lymphocytes from working against the disease.

31 Aug 2012

Human Vaccines & Immunotherapeutics Special Focus provides critical view on cancer vaccines

In one of the most comprehensive peer-reviewed discussions on cancer vaccines and immunotherapeutics, a Special Focus in the journal Human Vaccines & Immunotherapeutics provides a critical view on cancer vaccines and a discussion on best approaches for the future.

28 Aug 2012

Seattle Genetics commences everolimus-SGN-75 combination phase Ib clinical trial for advanced RCC

Seattle Genetics, Inc. today announced the initiation of a phase Ib clinical trial evaluating SGN-75 in combination with everolimus (Afinitor) for patients with advanced metastatic renal cell carcinoma (RCC).

24 Aug 2012

NW Bio receives MHRA approval to initiate DCVax-L Phase III GBM brain cancer trial in the U.K.

Northwest Biotherapeutics announced today that it has received approval from the Medicines and Healthcare Products Regulatory Agency (MHRA) of the United Kingdom, for the Company's 300-patient Phase III clinical trial of DCVax-L immune therapy for Glioblastoma multiforme brain cancer (GBM) to proceed in the U.K.

24 Aug 2012

New results describe development of DC cancer vaccine with enhanced immunogenic potential

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, and collaborators at Radboud University Nijmegen Medical Centre in the Netherlands announced today that they have published new pre-clinical results in the journal Cancer Immunology Immunotherapy describing the development of a dendritic cell (DC) cancer vaccine with enhanced immunogenic potential.

23 Aug 2012

Radiation therapy alone no longer the best choice for early follicular lymphoma

A University of Rochester Medical Center study published in the Journal of Clinical Oncology, challenges treatment guidelines for early stage follicular lymphoma, concluding that six different therapies can bring a remission, particularly if the patient is carefully examined and staged at diagnosis.

22 Aug 2012

Two eminent cancer specialists and EORTC to be recognized at ESMO 2012 Congress

The European Society for Medical Oncology (ESMO) announced today the names of two eminent cancer specialists and one European institution that will be recognized for their contribution to the advancement of medical oncology at the ESMO 2012 Congress.

17 Aug 2012

Combination of Zelboraf and immunotherapy increases tumor responses and survival in MM

Combining the recently approved BRAF inhibitor, Zelboraf with an engineered T cell immunotherapy to treat metastatic melanoma significantly increased tumor responses and survival in an animal model, researchers at UCLA's Jonsson Comprehensive Cancer Center have shown.

16 Aug 2012

Cedars-Sinai's ICT-107 doubles median survival of patients with malignant brain tumor

An experimental immune-based therapy more than doubled median survival of patients diagnosed with the most aggressive malignant brain tumor, Cedars-Sinai Medical Center researchers reported in Cancer Immunology, Immunotherapy, published online Aug. 3.

16 Aug 2012

Data from IMUC’s ICT-107 Phase I trial on glioblastoma multiforme accepted for publication

ImmunoCellular Therapeutics announced today that clinical data from its Phase I trial of ICT-107 was accepted for publication, and is currently in the online edition of the prestigious medical journal Cancer Immunology, Immunotherapy.

9 Aug 2012

Changes in monocytes are biomarker for amyotrophic lateral sclerosis

Researchers from Brigham and Women's Hospital (BWH) are the first to discover that changes in monocytes (a type of white blood cell) are a biomarker for amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease. This finding also brings the medical community a step closer toward a new treatment for the debilitating neurological disease that affects approximately 30,000 Americans.

7 Aug 2012

Topline results from Janssen bapineuzumab Phase 3 trial on mild-to-moderate Alzheimer's

Pfizer Inc. announced today that the co-primary clinical endpoints, change in cognitive and functional performance compared to placebo, were not met in the Janssen Alzheimer Immunotherapy R&D LLC (Janssen AI)-led Phase 3 trial of intravenous (IV) bapineuzumab in patients with mild-to-moderate Alzheimer's disease who do not carry the ApoE4 (apolipoprotein E epsilon 4) genotype (Study 301).

7 Aug 2012

Immunotherapy News and Research

Latest Immunotherapy News and Research

Jennerex Phase 2 JX-594 clinical data for hepatocellular carcinoma presented at ILCA meeting

Janssen, ImmuNext partner to develop novel cancer therapeutics

ImmunoCellular completes enrollment in ICT-107 Phase II trial for glioblastoma

ImmusanT commences Nexvax2 clinical trials for celiac disease in New Zealand, Australia and the U.S.

EC grants marketing authorization for Pfizer’s INLYTA to treat renal cell carcinoma

Potassium-channel autoimmunity linked to chronic pain

VLST, Pfizer enter in-licensing agreement for anti-CD40 monoclonal antibody

Promising results with SLIT for childhood grass pollen allergy

Study explains why some cancer vaccines are not as effective as hoped

Human Vaccines & Immunotherapeutics Special Focus provides critical view on cancer vaccines

Seattle Genetics commences everolimus-SGN-75 combination phase Ib clinical trial for advanced RCC

NW Bio receives MHRA approval to initiate DCVax-L Phase III GBM brain cancer trial in the U.K.

New results describe development of DC cancer vaccine with enhanced immunogenic potential

Radiation therapy alone no longer the best choice for early follicular lymphoma

Two eminent cancer specialists and EORTC to be recognized at ESMO 2012 Congress

Combination of Zelboraf and immunotherapy increases tumor responses and survival in MM

Cedars-Sinai's ICT-107 doubles median survival of patients with malignant brain tumor

Data from IMUC’s ICT-107 Phase I trial on glioblastoma multiforme accepted for publication

Changes in monocytes are biomarker for amyotrophic lateral sclerosis

Topline results from Janssen bapineuzumab Phase 3 trial on mild-to-moderate Alzheimer's

eBook: Cell-based technologies in drug discovery and Immunotherapy eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Immunotherapy News and Research

Latest Immunotherapy News and Research

eBook: Cell-based technologies in drug discovery and Immunotherapy eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in